Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair ConcentrationsCatherine A. Koss, Monica Gandhi, Sharon L. Hillier et al.|AIDS Research and Human Retroviruses|2017Cited by 57
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialMark A. Marzinke, Sybil Hosek, Susan H. Eshleman et al.|The Lancet HIV|2023Cited by 14
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083Meredith E. Clement, Richard Novák, Brett Hanscom et al.|Clinical Infectious Diseases|2024Cited by 0
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialAdeola Adeyeye, Zhe Wang, Beatriz Grinsztejn et al.|UNC Libraries|2025Cited by 0